• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Trastuzumab use in patients with durable complete response in HER2-amplified metastatic breast cancer: to continue or not to continue.

作者信息

Butterbaugh S T, Patel R, Romond E H, Mathew A

机构信息

Division of Medical Oncology, Markey Cancer Center, University of Kentucky, Lexington, USA.

Director, Kerala Cancer Care, Kochi, Kerala, India.

出版信息

Ann Oncol. 2017 Dec 1;28(12):3098-3099. doi: 10.1093/annonc/mdx532.

DOI:10.1093/annonc/mdx532
PMID:28950320
Abstract
摘要

相似文献

1
Trastuzumab use in patients with durable complete response in HER2-amplified metastatic breast cancer: to continue or not to continue.曲妥珠单抗在HER2扩增的转移性乳腺癌中获得持久完全缓解的患者中的应用：继续还是停止。
Ann Oncol. 2017 Dec 1;28(12):3098-3099. doi: 10.1093/annonc/mdx532.
2
Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.多中心 III 期随机临床试验比较多西他赛和曲妥珠单抗与多西他赛、卡铂和曲妥珠单抗作为人表皮生长因子受体 2（HER2）基因扩增转移性乳腺癌（BCIRG 007 研究）一线化疗的疗效：两种高度有效的治疗方案。
J Clin Oncol. 2011 Jan 10;29(2):149-56. doi: 10.1200/JCO.2010.28.6450. Epub 2010 Nov 29.
3
Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis.每周使用紫杉醇联合卡铂，联合或不联合曲妥珠单抗作为HER2阳性乳腺癌的新辅助化疗：HER2扩增的缺失及其对反应和预后的影响。
Breast Cancer Res Treat. 2017 Jan;161(2):259-267. doi: 10.1007/s10549-016-4064-9. Epub 2016 Nov 24.
4
Clinical implications of intratumoral heterogeneity of HER2 gene amplification in locally advanced HER2-positive breast cancer patients.局部晚期HER2阳性乳腺癌患者中HER2基因扩增的肿瘤内异质性的临床意义
Future Oncol. 2015 Sep;11(18):2495-7. doi: 10.2217/fon.15.164. Epub 2015 Aug 17.
5
Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer.曲妥珠单抗联合小剂量环磷酰胺和甲氨蝶呤治疗HER-2阳性转移性乳腺癌患者。
BMC Cancer. 2006 Sep 15;6:225. doi: 10.1186/1471-2407-6-225.
6
The role of p95HER2 in trastuzumab resistance in breast cancer.p95HER2在乳腺癌曲妥珠单抗耐药中的作用。
J BUON. 2016 Mar-Apr;21(2):382-9.
7
Role of MEL-18 Amplification in Anti-HER2 Therapy of Breast Cancer.MEL-18 扩增在乳腺癌抗 HER2 治疗中的作用。
J Natl Cancer Inst. 2019 Jun 1;111(6):609-619. doi: 10.1093/jnci/djy151.
8
Current and future anti-HER2 therapy in breast cancer.乳腺癌当前及未来的抗HER2治疗
J BUON. 2013 Jan-Mar;18(1):4-16.
9
A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial.一项探索贝伐珠单抗联合无化疗方案在人表皮生长因子受体 2（HER2）阳性转移性乳腺癌中作用的随机 2 期研究：HAT 研究（BOOG 2008-2003），荷兰乳腺癌研究组的一项试验。
Cancer. 2016 Oct;122(19):2961-70. doi: 10.1002/cncr.30141. Epub 2016 Jun 17.
10
Dual HER2 blockade slows metastatic breast cancer.双重HER2阻断可延缓转移性乳腺癌的进展。
Cancer Discov. 2012 Jan;2(1):OF4. doi: 10.1158/2159-8290.CD-ND121511OL-12. Epub 2011 Dec 15.

引用本文的文献

1
Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression.曲妥珠单抗治疗后进展的 HER2 阳性转移性乳腺癌患者停用曲妥珠单抗。
Sci Rep. 2023 May 31;13(1):8779. doi: 10.1038/s41598-023-35715-2.
2
HER2-Directed Therapy in Advanced Breast Cancer: Benefits and Risks.晚期乳腺癌的HER2靶向治疗：益处与风险
Onco Targets Ther. 2023 Feb 19;16:115-132. doi: 10.2147/OTT.S335934. eCollection 2023.
3
No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer.
一线抗 HER2 靶向治疗转移性乳腺癌长期缓解者无疾病证据与残留疾病。
Br J Cancer. 2022 Apr;126(6):881-888. doi: 10.1038/s41416-021-01676-4. Epub 2021 Dec 20.
4
Dual HER2 Blockade in Neoadjuvant Treatment of HER2+ Breast Cancer: A Meta-Analysis and Review.新辅助治疗 HER2+乳腺癌的双 HER2 阻断：荟萃分析和综述。
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820960721. doi: 10.1177/1533033820960721.